KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EPS (Weighted Average and Diluted) (2016 - 2025)

Teva Pharmaceutical Industries' EPS (Weighted Average and Diluted) history spans 10 years, with the latest figure at $0.41 for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 315.79% year-over-year to $0.41, compared with a TTM value of $1.2 through Dec 2025, up 182.76%, and an annual FY2025 reading of $1.21, up 183.45% over the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.41 at Teva Pharmaceutical Industries, up from $0.37 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.41 in Q4 2023, with the low at -$1.17 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.13, with a median of -$0.04 recorded in 2024.
  • Year-over-year, EPS (Weighted Average and Diluted) crashed 1328.57% in 2022 and then soared 315.79% in 2025.
  • Tracing TEVA's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.14 in 2021, then crashed by 735.71% to -$1.17 in 2022, then soared by 135.04% to $0.41 in 2023, then plummeted by 146.34% to -$0.19 in 2024, then soared by 315.79% to $0.41 in 2025.
  • Per Business Quant, the three most recent readings for TEVA's EPS (Weighted Average and Diluted) are $0.41 (Q4 2025), $0.37 (Q3 2025), and $0.24 (Q2 2025).